Description

Mirabegron & Solifenacin Tablets ER 25/5 Mg

Mirabegron & Solifenacin Tablets ER 25/5 Mg is a prescription fixed-dose combination tablet used in the management of overactive bladder (OAB) symptoms in adults. This formulation combines Mirabegron extended-release 25 mg, a β3-adrenergic receptor agonist, and Solifenacin succinate 5 mg, an antimuscarinic agent. Together, they improve bladder storage capacity, reduce urinary urgency, frequency, and urge incontinence episodes when prescribed by a healthcare provider.

How Mirabegron & Solifenacin Tablets ER 25/5 Mg Work

Combination therapy with Mirabegron and Solifenacin targets two complementary pathways involved in bladder function.This therapy is part of a comprehensive approach that includes lifestyle modification and pharmacological management, as outlined in overactive bladder causes and treatment guidance.

Mechanism of Action

• Mirabegron: Activates β3-adrenergic receptors in the bladder’s detrusor muscle to increase bladder capacity during urine storage.

• Solifenacin: Antagonizes muscarinic receptors in the bladder, reducing involuntary contractions and urinary urgency.

• Together, these actions help improve urinary symptoms more effectively than either agent alone for many patients.

This dual mechanism supports symptom control and improves patient quality of life when used as directed by a clinician.

Uses of Mirabegron & Solifenacin Tablets ER 25/5 Mg

The dosage of Mirabegron & Solifenacin Tablets ER 25/5 Mg should be determined by a qualified healthcare provider based on the patient’s clinical condition and response to treatment. Patients and prescribers can refer to

Mirabegron extended-release tablets medical information for detailed prescribing guidance, pharmacokinetics, and safety profiles to support optimal dosing decisions.

Therapeutic Indications

Mirabegron & Solifenacin Tablets ER 25/5 Mg are prescribed for:

• Management of overactive bladder (OAB)

• Treatment of urinary urgency

• Reduction in urge incontinence episodes

• Control of increased urinary frequency

• Patients not adequately responsive to monotherapy

Dosage and Administration

The dosage of Mirabegron & Solifenacin Tablets ER 25/5 Mg should be individualized based on clinical response and tolerability and prescribed by a healthcare professional.

Administration Guidelines

• Take once daily orally

• Swallow the tablet whole with water

• Can be taken with or without food

• Do not crush, chew, or divide the tablet to maintain extended-release properties

• Follow the prescribing clinician’s instructions carefully

For specific physician-approved dosing guidance, refer to trusted clinical information such as Mirabegron extended-release tablets medical information.

Side Effects of Mirabegron & Solifenacin Tablets ER 25/5 Mg

Like all medications, this combination may cause side effects. Patients should discuss any concerns with their healthcare provider.

Common Side Effects

• Dry mouth

• Constipation

• Headache

• Dizziness

• Urinary tract infection

• Elevated blood pressure

Less Common Side Effects

• Blurred vision

• Abdominal discomfort

• Difficulty emptying bladder

• Palpitations

If severe or persistent adverse effects occur, patients should seek medical advice.

Warnings and Precautions

Before starting this medication, patients should inform their healthcare provider of their full medical history.

Important Safety Information

• Use with caution in patients with uncontrolled hypertension

• Dose adjustment may be necessary in renal or hepatic impairment

• Not recommended for patients with urinary retention

• Avoid alcohol while taking this medication due to additive side effects (e.g., dizziness)

• Follow all medical instructions and report any unusual symptoms

See reputable clinical sources for complete safety and contraindication details.

Storage Instructions

• Store at below 25°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

• Keep in original packaging until use